Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 30,000 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $60.99, for a total transaction of $1,829,700.00. Following the transaction, the chief executive officer owned 660,482 shares of the company’s stock, valued at $40,282,797.18. This trade represents a 4.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Nello Mainolfi also recently made the following trade(s):

• On Tuesday, September 16th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $49.00, for a total transaction of $1,470,000.00.

Kymera Therapeutics Stock Down 3.1%

KYMR stock opened at $60.03 on Thursday. Kymera Therapeutics, Inc. has a 52 week low of $19.44 and a 52 week high of $63.96. The company has a fifty day simple moving average of $51.69 and a two-hundred day simple moving average of $43.54. The firm has a market capitalization of $4.29 billion, a P/E ratio of -17.30 and a beta of 2.26.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The business had revenue of $11.48 million for the quarter, compared to the consensus estimate of $17.37 million. During the same quarter last year, the business earned ($0.58) EPS. Kymera Therapeutics’s revenue for the quarter was down 55.1% compared to the same quarter last year. As a group, analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Kymera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 16th. BTIG Research raised their target price on shares of Kymera Therapeutics from $59.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, October 22nd. HC Wainwright raised their target price on shares of Kymera Therapeutics from $60.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, September 18th. Mizuho assumed coverage on shares of Kymera Therapeutics in a report on Tuesday, October 21st. They issued an “outperform” rating and a $81.00 target price for the company. Finally, Royal Bank Of Canada assumed coverage on shares of Kymera Therapeutics in a report on Tuesday, September 16th. They issued an “outperform” rating and a $70.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $65.45.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in KYMR. Farther Finance Advisors LLC increased its stake in Kymera Therapeutics by 642.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock worth $27,000 after buying an additional 540 shares during the period. PNC Financial Services Group Inc. increased its stake in Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after buying an additional 770 shares during the period. Osaic Holdings Inc. increased its stake in Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in Kymera Therapeutics in the 1st quarter worth about $68,000. Finally, KBC Group NV increased its position in Kymera Therapeutics by 15.2% during the 1st quarter. KBC Group NV now owns 2,479 shares of the company’s stock valued at $68,000 after purchasing an additional 328 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.